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 Emerging Role of MicroRNAs and Long Noncoding 
RNAs in Respiratory Disease 
 Richard  Booton ,  PhD ;  and  Mark A.  Lindsay ,  PhD 
 
 The advent of techniques such as microarrays and high-throughput sequencing has revo-
lutionized our ability to examine messenger RNA (mRNA) expression within the respiratory 
system. Importantly, these approaches have also uncovered the widespread expression of 
“noncoding RNAs,” including microRNAs and long noncoding RNAs, which impact biologic 
responses through the regulation of mRNA transcription and/or translation. To date, most 
studies of the role of noncoding RNAs have focused on microRNAs, which regulate mRNA 
translation via the RNA interference pathway. These studies have shown changes in microRNA 
expression in cells and tissues derived from patients with asthma, pulmonary ﬁ brosis, cystic 
ﬁ brosis, COPD, and non-small cell lung cancer. Although the evidence is currently limited, we 
review the work that has been carried out in cell and animal models that has identiﬁ ed the 
function and mechanism of action of a small number of these microRNAs in disease etiology. 
In addition to microRNAs, we assess the emerging evidence that long noncoding RNAs reg-
ulate respiratory phenotype. Because these investigations into long noncoding RNAs were 
performed almost exclusively in non-small cell lung cancer, future work will need to extend 
these into other respiratory diseases and to analyze how microRNAs and long noncoding RNAs 
interact to regulate mRNA expression. From a clinical perspective, the targeting of noncoding 
RNAs as a novel therapeutic approach will require a deeper understanding of their function 
and mechanism of action. However, in the short term, changes in miRNA and long noncoding 
RNA expression are likely to be of use as biomarkers for disease stratiﬁ cation and/or assess-
ment of drug action.  CHEST 2014;  146 ( 1 ): 193 - 204 
 ABBREVIATIONS :  CF  5 cystic fibrosis ;  CFTR 5 cystic fibrosis transmembrane conductance regulator ; 
 HASM  5 human airway smooth muscle ;  IPF  5 idiopathic pulmonary fi brosis ;  lncRNA  5 long noncoding 
RNA ;  MALAT1 5  metastasis associated in lung adenocarcinoma transcript 1 ;  MEG3  5 maternally 
expressed gene 3 ;  miRNA  5 microRNA ;  mRNA  5 messenger RNA ;  ncRNA  5 noncoding RNA ;  NSCLC  5 
non-small cell lung cancer ;  SCAL1  5 smoke and cancer-associated long noncoding RNA-1 ;  TGF  5 
transforming growth factor 
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 Evidence is accumulating that shows that 
large sections of the genome are transcribed 
into noncoding RNAs (ncRNAs) (ie, RNA 
sequences that are not translated into 
proteins). Th e exact proportions are still an 
area of controversy. Th us, the  Encyclopedia 
of DNA Elements (the “ENCODE” project 
that aims to catalog all the functional 
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elements in human DNA) has concluded that approxi-
mately 80% of DNA is functional and, importantly, that 
the majority (approximately 62%) is transcribed into 
RNA.  1  However, a number of investigators have ques-
tioned these conclusions, most notably whether ncRNA 
is indeed functional.  2  
 Despite this controversy, there are many ncRNAs with 
demonstrated function. At the present time, ncRNAs are 
divided broadly into three groups: housekeeping RNAs, 
short ncRNAs (< 200 nucleotides), and long ncRNAs 
(lncRNAs) (> 200 nucleotides) ( Fig 1 ).  3 - 6  Th e house-
keeping RNAs include ribosomal RNA, transfer RNA, 
small nucleolar RNA, and small nuclear RNA. By far the 
largest component is the ribosomal RNAs (5S, 18S, and 
28S), which represent > 90% of total RNA in mamma-
lian cells and which interact with proteins and transfer 
RNAs to form the functional ribosome complex that is 
central to translation. Th e best characterized family of 
short ncRNAs is the microRNAs (miRNAs), which 
regulate the translation of messenger RNA (mRNA) into 
protein via the RNA interference pathway. Interestingly, 
recent sequencing studies have identifi ed a tranche of 
new small RNA families that are commonly located at 
sites of active transcription; they include transcription 
initiation RNAs, splice site RNAs, and promoter-associated 
small RNAs.  3  Finally, the least characterized but largest 
group by number is the lncRNAs, which are thought 
to regulate both mRNA transcription and/or transla-
tion. Given the paucity of information on the many 
thousands of lncRNAs, these are commonly subdivided 
by sequence and position relative to protein coding 
genes into antisense lncRNAs, pseudogenes lncRNAs, 
intronic lncRNAs, and intergenic lncRNAs. To date, 
most studies of the role of ncRNAs in respiratory 
dis ease have concerned miRNAs, which will, therefore, 
form the focus of the current review. However, we also 
plan to highlight the emerging role of lncRNAs. 
 miRNAs and the RNA Interference Pathway 
 As implied by the name, miRNAs are small 21 to 23 
nucleotide RNA sequences that are produced from 
primary miRNA transcripts by the sequential action of 
two RNase III endonucleases, Drosha and Dicer ( Fig 2 ).  7  
Th e initial primary miRNA transcripts are essentially 
identical to mRNAs but lack the translational start 
codon (AUG) and fold to produce a characteristic 
hairpin structure. Th ese are recognized by Drosha and 
the DiGeorge syndrome critical region gene 8 and 
cleaved in the nucleus to produce a precursor miRNA 
with a stem-loop structure and a length of approxi-
mately 70 to 90 nucleotides ( Fig 2 ). Th e precursor 
miRNA is exported into the cytoplasm and is cleaved by 
Dicer to produce an approximately 22-nucleotide 
double-stranded RNA. Th is is subsequently unwound, 
and a single miRNA strand is loaded into the Ago2 
protein, an essential component of the RNA-induced 
silencing complex. Within the RNA-induced silencing 
complex, miRNAs are able to induce mRNA degrada-
tion and/or inhibit the translation of target mRNAs by a 
mechanism titled RNA interference. Th is process 
  
 Figure 1 –  Classifi cation of miRNAs and lncRNAs. Noncoding RNAs (shown in blue) are commonly divided into housekeeping RNAs (ribosomal 
RNA, transfer RNAs, small nucleolar RNAs, and small nuclear RNAs [not shown]), small noncoding RNAs (, 200 nucleotides), and lncRNAs 
(. 200 nucleotides). Th e best characterized group of small noncoding RNAs is the miRNAs, which are produced from primary miRNAs transcripts by 
the sequential action of endonucleases (see  Fig 2 ). Primary miRNAs are located within both intronic and intergenic regions of protein-coding mRNAs 
(shown in red). Th e lncRNAs are also classifi ed by their structure and position relative to mRNAs and include intronic lncRNA, antisense lncRNA, 
intergenic lncRNA, and pseudogenes. lncRNA 5 long noncoding RNA; miRNA 5 microRNA; mRNA 5 messenger RNA. 
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involves noncomplementary binding between the 
miRNAs, particularly the seed region at residues 2 to 7, 
and the 3 9 -untranslated region of the target mRNA. 
Importantly, the noncomplementary nature of this 
binding and the short length of the seed region mean 
that miRNAs can target multiple mRNAs, whereas 
individual mRNAs contain target sites for multiple 
miRNAs. Indeed, it is predicted that about 60% of 
mRNAs can act as targets for miRNAs.  8  
 What Is the Physiologic Function of miRNAs 
in the Respiratory System? 
 Before examining the role of miRNAs in respiratory 
disease, it is important to understand their function 
under physiologic conditions. In general, analysis of 
multiple organs and cells indicates that miRNAs have a 
dual role as both regulators of development (in nondif-
ferentiated cells) and in the maintenance of homeostasis 
in diff erentiated cells.  9 , 10  In the respiratory system, their 
importance in the former is underlined by the wide-
spread changes in miRNA expression observed during 
lung development  11  and in studies in Dicer knockout 
mice, in which miRNA processing is disrupted, that 
demonstrate a lethal phenotype resulting from impaired 
lung growth.  12  Our understanding of the role of indi-
vidual miRNAs during lung development is limited, 
although profi ling studies have shown downregulation 
of the miR-154 family and the miR-17 to about 92 
cluster (miR-17, -18a, -19a, -20a, 19b-1, and -92-1) and 
increases in the miR-29 family and miR-127.  11 , 13  
Blocking the reduction in expression of the miR-17 to 
about 92 cluster using transgenic mice resulted in 
abnormal (and lethal) lung development that was 
characterized by continued proliferation and impaired 
diff erentiation of epithelial cells.  14  
 Th e centrality of miRNAs in the maintenance of 
homeostasis in the adult (diff erentiated) lung is sup-
ported by expression studies that demonstrate no 
change in miRNA expression during the process of lung 
aging.  15  Examination of the profi le of expression in the 
adult lung shows that this is dominated by a small 
number of miRNAs, with miR-21 being the most highly 
expressed at about 30% of the total ( Table 1 ). Indeed, when 
added together, it was found that the 10 and 50 most 
expressed miRNAs represent approximately 68% and 
approximately 97% of the total, respectively ( Table 1 ). 
Interestingly, although some miRNAs are expressed in a 
cell-specifi c manner, many of these highly expressed 
  
 Figure 2 –  Mechanism of miRNA-mediated RNA interference. Following polymerase II-mediated transcription, the primary miRNA transcript folds to 
produce a characteristic hairpin structure. Th is is recognized by Drosha and DGCR8, which positions the endonuclease Drosha to cleave the hairpin 
structure at 11 nucleotides from the base and release the pre-miRNA. Th e pre-miRNA is then transported to the cytoplasm, where the hairpin is 
removed by the second endonuclease, Dicer, and one strand of the resulting double-stranded miRNA is removed by Ago2 to produce the mature 
miRNAs. Bound within the Ago2 with multiple other proteins, the miRNA-Ago2 complex searches for noncomplementary sequences within the 3 9 UTR 
of mRNA. Once mRNA-miRNA binding occurs, this results in either mRNA degradation or blockage of mRNA translation. 3 9 UTR 5 3 9 -untranslated 
region; DGCR8 5 DiGeorge syndrome critical region gene 8; pre-miRNA 5 precursor miRNA; RISC 5 RNA-induced silencing complex. See  Figure 1 
legend for expansion of other abbreviations. 
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 miRNA
% Total miRNA 
Expression Disease Association 
 mir-27b 0.22 … 
 mir-29c 0.21 Lung development, IPF 
 mir-141 0.19 … 
 mir-26a-2 0.19 Asthma 
 mir-23b 0.19 … 
 mir-145 0.17 Asthma, IPF, CF 
 mir-199a-1 0.16 IPF, COPD 
 mir-181a-2 0.15 … 
 CF 5 cystic ﬁ brosis; IPF 5 idiopathic pulmonary ﬁ brosis; miRNA 5 
microRNA; NSCLC 5 non-small cell lung cancer. 
TABLE 1 ] (continued)
miRNAs, including let-7 and miR-21, are common 
among all diff erentiated cells/tissues (miRNA expression 
in specifi c cells and tissues can be found at  http://www.
mirbase.org ). Th is has led to speculation that they 
regulate common phenotypes such as proliferation and 
apoptosis and that changes in their expression are 
associated with cancer (see the miRNAs and Non-small 
Cell Lung Cancer section). 
 Attempts to elucidate the role of miRNAs have primarily 
involved the measurement of their diff erential expres-
sion in cells/tissues obtained from patients with the 
relevant respiratory disease, whereas subsequent 
functional and mechanistic studies have involved 
overexpression and inhibition of these miRNAs in cell 
and animal models.  16  We have, therefore, adopted this 
systematic approach to reviewing the role of miRNAs in 
various respiratory diseases. 
 miRNAs and Asthma 
 Asthma is characterized by chronic airway infl ammation 
and reversible airfl ow obstruction, the latter commonly 
occurring in response to environmental challenges such 
as allergens and infections. Initial studies using airway 
biopsy specimens obtained from mild asthmatics were 
unable to show changes in miRNA expression, although 
it was speculated that this may have resulted from the 
mixed cell populations in the biopsy specimens and/or 
the phenotype of those with mild asthma.  17  Th ese 
problems were addressed subsequently by two studies 
using isolated bronchial epithelial cells, in which 
Jardim et al  18  showed diff erential expression of 66 miRNAs 
in patients with mild asthma, and Solberg et al  19  
demonstrated changes in 217 miRNAs and 200 miRNAs 
in steroid-naive and steroid-using patients with asthma 
respectively. Of relevance, the variations in miRNAs 
observed by Solberg et al  19  could be recapitulated by 
 TABLE 1 ]  Relative Expression of miRNAs in 
Human Lung and Their Association With 
Respiratory Disease 
 miRNA
% Total miRNA 
Expression Disease Association 
 mir-21 29.61 Asthma, IPF, NSCLC 
 mir-22 10.63 … 
 mir-143 6.15 … 
 mir-203 4.97 … 
 mir-148a 4.44 … 
 mir-99b 2.97 … 
 mir-10a 2.57 … 
 mir-103-1 2.31 … 
 mir-182 2.27 … 
 mir-30a 1.95 … 
 let-7b 1.92 Asthma, IPF, NSCLC 
 mir-10b 1.90 … 
 mir-92a-2 1.79 … 
 mir-205 1.67 … 
 mir-183 1.62 … 
 let-7a-2 1.38 Asthma, IPF, NSCLC 
 mir-101-1 1.34 CF 
 mir-200c 1.24 IPF 
 mir-25 1.21 Asthma 
 mir-30e 1.15 … 
 mir-93 0.93 … 
 mir-375 0.90 … 
 mir-30d 0.81 … 
 let-7f-2 0.69 Asthma, IPF, NSCLC 
 let-7a-3 0.69 Asthma, IPF, NSCLC 
 let-7a-1 0.69 Asthma, IPF, NSCLC 
 mir-29a 0.66 Lung development, IPF 
 mir-100 0.63 … 
 mir-28 0.56 … 
 mir-23a 0.55 … 
 mir-9-1 0.38 … 
 mir-9-2 0.38 … 
 mir-126 0.37 Asthma, CF 
 mir-151 0.35 … 
 mir-142 0.34 … 
 mir-199b 0.34 IPF 
 mir-210 0.31 … 
 mir-181a-1 0.29 … 
 mir-24-2 0.28 … 
 mir-1307 0.27 … 
 mir-199a-2 0.27 IPF, COPD 
 mir-27a 0.24 … 
(Continued)
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exposing epithelial cells to IL-13, a cytokine implicated 
in the development of asthma.  19  
 T cells are believed to be important orchestrators of the 
chronic infl ammatory response in asthma. Circulating 
CD4 + T cells from mild and moderate asthmatics 
showed diff erential expression of miR-132, miR-223, 
miR-374a, and miR-1290, whereas CD3 + T cells from 
bronchial biopsy specimens of patients with mild 
asthma exhibited downregulation of miR-125b, miR-19a, 
miR-19b, and miR-106b.  20  Our own studies using 
circulating CD4 + and CD8 + T cells showed downregula-
tion of miR-146a and miR-146b in patients with severe 
asthma, but not in those with nonsevere asthma.  21  Given 
that miR-146a and miR-146b negatively regulate the 
immune response,  22  we speculated that a reduction in 
their expression might contribute toward T-cell activa-
tion. In addition to studies of T cells, a number of 
reports have examined peripheral blood mononuclear 
cells and have shown miR-192 downregulation in mild 
asthmatics  23  and miR-211 and miR-485-3p upregulation 
in pediatric patients with asthma.  24 , 25  
 In addition to their role in airway constriction, human 
airway smooth muscle cells (HASMs) are thought to 
contribute to the airway thickening (hypertrophy) and 
the chronic infl ammatory response that is characteristic 
of asthma. Indeed, isolated HASMs exhibit increased 
proliferation and release of infl ammatory mediators in 
response to exogenous stimulation.  26  At the present 
time, no studies have examined miRNA expression in 
asthmatic samples, although there are reports on the 
function of individual miRNAs in isolated HASMs. As 
detailed in  Table 2 ,  27-55  this includes a role for miR-
140-3p  35  and miR-133a  34  in contractility, miR-26a  31  and 
miR-221  26  in proliferation, and miR-25  30  and miR-221  26  
in the infl ammatory response. 
 Th e functional relevance of individual miRNAs has also 
been assessed using a number of mouse models of 
allergic asthma, including those induced using oval-
bumin, house dust mite, and IL-13 transgenics. Using 
intratracheal or intranasal delivery of antisense oligonu-
cleotides targeted at individual miRNAs, these studies 
have identifi ed potential roles for miR-21,  56  miR-126,  33 , 57  
miR-145,  58  miR-106a,  32  miR-1,  29  let-7,  27  and miR-221  25  
in the development of allergic asthma through the 
targeting of various cytokines and transcription factors 
( Table 2 ). 
 miRNAs and Idiopathic Pulmonary Fibrosis 
 Idiopathic pulmonary fi brosis (IPF) is localized to the 
lung interstitium, is characterized by fi brosis, and is 
thought to result from the excessive production of 
extracellular matrix components by fi broblasts and 
myofi broblasts. It is speculated that this results from an 
aberrant wound-healing response linked to excessive 
transforming growth factor (TGF)- b production. Most 
studies of the role of miRNAs in IPF have used a 
combination of human lung samples, isolated lung 
fi broblasts, and the bleomycin-induced mouse model of 
lung fi brosis. A range of miRNAs, including let-7d,  36  
miR-21,  38  miR-29,  59  miR-200,  60  miR-154,  61  the miR-17 to 
about 92 cluster,  37  miR-145,  40  and miR-199-5p, have 
been shown to be diff erentially expressed in human IPF 
lung tissue, TGF- b -stimulated fi broblasts, or both.  41  
With the exception of miR-154,  61  these changes in 
miRNA expression were confi rmed in bleomycin-
induced lung fi brosis. Crucially, inhibition of let-7d,  36  
miR-21,  38  miR-29,  39  miR-200,  60  the miR-17 to about 
92 cluster,  37  miR-145,  40  and miR-199-5p  41  was also 
shown to impact bleomycin-induced lung fi brosis in 
mice, suggesting that these miRNAs may represent 
novel therapeutic targets. 
 As with other respiratory diseases, the mechanism of 
action of only a small proportion of these miRNAs is 
understood ( Table 2 ). Interestingly, miR-29 is known to 
target a host of extracellular matrix proteins and has 
been implicated as a key regulator in a range of fi brotic 
diseases.  62  However, in the case of IPF, miR-29 also 
appears to target expression of TGF- b , connective tissue 
growth factor, and Smad3.  39  Also of potential mecha-
nistic relevance is the upregulation of the maternally 
imprinted miR-154 region.  61  Having shown previously 
that this region is downregulated during lung develop-
ment,  11  this has led to speculation that IPF represents a 
reversion to a fetal lung phenotype.  61  Finally, the 
expression of many of these miRNAs has been linked to 
the activation of Smad3, a key transcription factor in the 
TGF- b signaling pathway.  36 , 39  
 miRNAs and COPD 
 COPD is driven predominantly by long-term exposure 
to cigarette smoke, leading to destruction of the lung 
parenchyma (emphysema) and associated reduction in 
lung function. Other symptoms include airway infl am-
mation, as well as cough and mucus secretion (bronchi-
tis). Unlike miRNAs in asthma, IPF, and lung cancer, 
virtually nothing is known regarding the role of miRNAs 
in COPD. A report by Ezzie et al  63  compared the miRNA 
expression in lung tissue derived from smokers with 
and without COPD and identifi ed 70 miRNAs, includ-
ing miR-223, miR-1274a, and miR-15b, that were 
diff erentially expressed in smokers without COPD, 
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whereas miR-34a and miR-199a-5p were increased in 
smokers with COPD. Only two studies have examined 
the role of miRNAs in isolated cells from patients with 
COPD. Using human lung fi broblasts, Sato et al  64  observed 
reduced miR-146a expression in patients with COPD 
and showed that this increased expression of PGE 2 
through the targeting of COX-2  64  ( Table 2 ). Th e second 
publication by Lewis et al  65  showed that miR-1 was 
downregulated in quadriceps muscles and speculated that 
this is linked to the muscle weakness observed in COPD. 
 miRNAs and Non-small Cell Lung Cancer 
 As with COPD, non-small cell lung cancer (NSCLC) is 
thought to result from long-term exposure to cigarette 
smoke and can be divided roughly equally between 
adenocarcinoma and squamous cell carcinoma, which 
together account for approximately 80% of total lung 
cancers. Th ere are nearly 1,000 publications relating to 
miRNAs and lung cancer, and this short report will 
distill some of the major conclusions; readers are 
referred to more in-depth reviews.  66 - 68  
 Expression studies have identifi ed a number of miRNAs 
linked to NSCLC. Early studies demonstrated that 
reduced expression of the members of the let-7 family 
was associated with a poor prognosis.  69 - 71  Interestingly, 
let-7 acts as a tumor suppressor by targeting the 
downregulation of the tumor promoting proteins, ras, 
and HMGA2.  45 , 46  Other miRNAs that have been 
identifi ed as having a similar tumor-suppressing action 
include miR-15a,  47  miR-16,  47  miR-31,  51  miR-487b,  54  and 
miR-4423  72  by targeting myc and ras,  54  the cell cycle 
regulators Rb and G 1 cyclins,  47  the large tumor sup-
pressor 2,  51  and the epigenetic regulators, SUZ12, BMI1, 
and WNT5A  54  ( Table 2 ). In contrast, the expression of 
miR-155,  70 , 71  the miR-17 to about 92 cluster,  48  miR-
221/222,  53  miR-21,  49  miR-146b,  71  and miR-135b  52  is 
reduced in NSCLC. In this case, these miRNAs are 
thought to promote tumor formation because their 
reduced levels result in increased expression of their 
proteins targets. Th ese targets include many known 
tumor promoters including PTEN,  53  programmed cell 
death 4,  49  the sprouty  49  and hippo  52  pathway, and 
hypoxia-inducible factor-1a  48  ( Table 2 ). 
 miRNA and Cystic Fibrosis 
 As may be expected, the analysis of miRNA function in 
cystic fi brosis (CF) has focused exclusively on lung 
airway epithelial cells and has examined their role in 
regulating the expression of the cystic fi brosis trans-
membrane conductance regulator (CFTR) or in the 
innate immune response. 
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 A number of miRNAs, including miR-101, miR-145, 
miR-223, miR-384, miR-494, miR-509-3p, and miR-
1246, have been demonstrated to target CFTR expres-
sion.  73 - 77  However, only the expression of miR-145, 
miR-223, miR-494, and miR-509-3p were upregulated in 
patients with CF and shown to be further increased in 
response to infl ammatory mediators such as tumor 
necrosis factor- a , IL-1 b , and  Pseudomonas aerugi-
nosa .  76 , 77  A report by Amato et al  78  identifi ed a single 
nucleotide polymorphism within the 3 9 -untranslated 
region of a number of patients with CF and CFTR-
related disorders that do not contain mutations within 
the coding sequencing. Because this single nucleotide 
polymorphism was located within the predicted binding 
site for miR-433 and miR-509-3p, they speculated that 
it may act as a mild CFTR mutation by enhancing 
miRNA affi  nity, leading to downregulation in CFTR 
expression. Interestingly, a screening-based approach by 
Ramachandran et al  43  showed that miR-138 knockout 
enhanced CFTR abundance and activity. Importantly, 
this action was mediated through knockdown of the 
transcriptional regulatory protein SIN3A, which relieved 
the repression of multiple genes involved in CFTR 
biosynthesis and regulation.  43  
 In addition to their actions on CFTR, changes in 
miRNA expression in patients with CF are thought to 
impact the immune response to infection. Oglesby et al  42  
found that decreased expression of miR-126 in CF 
epithelial cells resulted in the elevation of target of Myb1 
(TOM1), a protein involved in regulating toll-like 
receptor- and tumor necrosis factor- a -induced signaling 
pathways. Similarly, Bhattacharyya et al  44  showed 
upregulation of miR-155 and speculated that targeting 
SHIP1 expression would in turn lead to activation of the 
PI3K/Akt pathway and the production of IL-8. In a 
subsequent report, Tsuchiya et al  79  showed that exposure 
of lung epithelial cells to  P aeruginosa resulted in 
suppression of miR-155 and increased production of a 
range of miRNAs including miR-215, which may impact 
the survival and immune response in the epithelial cells. 
 lncRNA in Respiratory Disease 
 Emerging evidence suggests that changes in lncRNA 
expression are associated with the development of 
various types of cancer.  80 - 82  It is, therefore, unsurprising 
that, as with miRNAs, most studies of the role of 
lncRNAs in respiratory disease have been performed in 
NSCLC. Indeed, one of the fi rst lncRNAs was discovered 
in a screen of genes associated with lung adenocarci-
noma and was named metastasis associated in lung 
adenocarcinoma transcript 1 (MALAT1).  83  Interestingly, 
this large noncoding transcript (> 8 kb) is expressed at 
high levels in most cells, and initial mechanistic studies 
indicated that the nuclear-localized MALAT1 regu-
lated alternative splicing through an interaction with 
serine/argi nine splicing factors.  84 , 85  However, more recent 
examination of knockdown in cell and animals models 
has shown that MALAT1 regulates gene expression and 
not splicing, and specifi cally those genes involved in cell 
migration, colony formation, and metastasis.  86 - 88  
 Two well-characterized and highly expressed lncRNAs 
whose levels are also increased in NSCLC are HOTAIR  89  
and H19.  90  HOTAIR, which is known to regulate 
chromatin structure through an interaction with the 
polycomb response complex 2, has been shown to 
upregulate cell migration and anchorage-independent 
cell growth.  89  Interestingly, a possible interaction 
between lncRNA and miRNAs has been uncovered from 
studies showing that the increased expression of the 
paternally imprinted H19 lncRNA may act as a sponge 
for let-7, thereby explaining the downregulation of this 
miRNA in NSCLC.  91  
 Expression changes in four additional lncRNAs have 
also been linked to NSCLC and/or COPD, including 
smoke and cancer-associated lncRNA-1 (SCAL1),  92  
GAS6-antisense 1,  93  maternally expressed gene 3 
(MEG3),  94  and lncRNA low expression in tumor.  95  
SCAL1, whose expression is driven by nuclear factor 
erthyroid 2-related factor, is increased in NSCLC and 
following exposure to cigarette smoke in vivo and in 
vitro.  92  A protective role for this lncRNA was indicated 
in studies that demonstrated increased cigarette 
smoke-induced toxicity following SCAL1 knockdown.  92  
In contrast, MEG3 expression was reduced in NSCLC, 
and overexpression of MEG3 increased MDM3 and p53 
expression, resulting in increased proliferation and 
reduced apoptosis.  94  Interestingly, we have also shown 
reduced expression of MEG3 in the circulating CD8+ 
T cells of patients with severe asthma, as well as the 
diff erential expression of an additional 18 lncRNAs.  21  
 miRNAs as Biomarkers of Respiratory Disease 
 In addition to their role in disease, there is now a 
growing literature to suggest that miRNAs obtained 
from either blood, tissue, or exhaled breath may provide 
reliable biomarkers for the diagnosis and prognosis of 
respiratory disease. A recent comparison of exhaled 
condensates showed consistent reduction in miRNA 
expression in asthmatic patients (miR-1248, let-7a, 
miR-155, miR-21, miR-328, and miR-133a) and patients 
with COPD (miR-21 and miR-328) compared with 
control subjects.  96  Examination of circulating exosomes, 
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which are vesicular structures released into the blood 
stream by cells, has also demonstrated diff erential 
expression of miRNAs, including let-7a and miR-21, in 
mild asthma  97  and increased expression of muscle-
specifi c miRNA species (miR-1, miR-133, miR-206, and 
miR-499) in patients with COPD that was suggestive of 
muscle breakdown.  98  As may be expected, there is a 
considerable body of biomarker work in NSCLC,  99 , 100  
including reports showing that tissue and plasma 
miRNA signatures can be correlated with prognosis and 
disease classifi cation.  101  As a specifi c example, laser 
capture from bronchial brushings was able to identify 
two miRNAs that could discriminate between small cell 
lung cancer and NSCLC (miR-29a and miR-375) and 
adenocarcinoma and squamous cell carcinoma (miR-
205 and miR-34a).  102  
 Conclusions 
 Th ere is now increasing evidence that the expression of 
miRNAs is altered in the airways and lungs of patients 
with a broad range of respiratory diseases. Whether 
these are simply a refl ection of the disease or an impor-
tant mediator of the underlying pathology has yet to be 
determined. However, knockdown studies in animal 
models of asthma and IPF suggest that miRNAs are 
indeed important in the cause of disease and may off er 
potential therapeutic targets using approaches such as 
antisense oligonucleotides and short interfering RNAs. 
Although not related to respiratory disease, the targeting 
of the liver-specifi c miR-122 using an antisense-based 
approach is currently undergoing human trials for the 
treatment of the hepatitis C virus.  103  Given the accessi-
bility of the lung to topical administration, this approach 
may also be of use in tackling respiratory disease.  104  In 
contrast to miRNAs, much less is known regarding the 
role of the many thousands of lncRNAs, and this is likely 
to provide an exciting and fertile new area of scientifi c 
discovery. However, given that therapeutic modulation 
of ncRNAs is a medium to long prospect (5-10 years), it 
is likely that their short-term application will be as 
biomarkers in disease classifi cation and/or the assess-
ment of novel drugs. 
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